Anti-TACE [D1 (A12)]

Absolute Antibody

Anti-TACE [D1 (A12)]

9

TACE (CD156b) has proved capable of cleaving epidermal growth factor receptor (EGFR) ligands, extracellular Notch1, cell-surface receptors, and adhesion molecules. As proteolytic cleavage is an indispensable activation event for many of these substrates, TACE has emerged as an attractive therapeutic target for the treatment of cancer and rheumatoid arthritis. This cross-domain human antibody is a selective TACE antagonist and provides a unique alternative to smallmolecule metalloprotease inhibition. Note from inventor: D1(A12) is conformation sensitive and sees only a specific form of the native enzyme (reflecting its redox state). It does not work by IHC or WB. It was designed as a potential drug, active in native situations.

Neutralisation/Blocking

Research Use Only

Monoclonal

D1 (A12)

ADAM17

ADAM metallopeptidase domain 17

a disintegrin and metalloproteinase 17; ADAM metallopeptidase domain 18; ADAM18; cartilage snake venom-like protease; CD156B; CSVP; disintegrin and metalloproteinase domain-containing protein 17; NISBD; NISBD1; snake venom-like protease; TACE; TNF-alpha convertase; TNF-alpha convertase enzyme; TNF-alpha converting enzyme; tumor necrosis factor, alpha, converting enzyme

Human

IgG1

Disintegrin and metalloproteinase domain-containing protein 17

This reformatted human antibody was made using the variable domain sequences of the original human scFv format, for improved compatibility with existing reagents, assays and techniques.

-20°C,2°C to 8°C

12352203